Schrödinger, Inc.
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $1.18B |
| Revenue | $255M |
| Net Income | $-103M |
| Total Assets | $634M |
| Net Assets | $314M |
| Employees | 850 |
| Value | |
| P/B | 3.76x |
| P/S | 4.62x |
| FCF Yield | -12.60% |
| Profitability | |
| ROE | -33.00% |
| ROA | -16.32% |
| Op. Margin | -64.65% |
| Revenue Growth | -1.62% |
| Financial Health | |
| Debt Ratio | 102.26% |
| Total Debt | $107M |
| FCF | $-148M |
| Cash | $260M |
| Current Ratio | 2.74x |
| Dividend | |
| Div. Yield | 0.00% |
| Payout Ratio | 0.00% |
| Performance | |
| 1Y Return | -25.13% |
| 1M Return | 31.44% |
| From 52W High | -42.96% |
| 1Y MDD | -57.96% |
| Trading | |
| Volume | 1,462,389 shares |
| Trading Value | $23M |
| Per Share | |
| EPS | $-1.41 |
| BPS | $4.94 |
Company Info
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.